Spinal Cord Stimulation for Postoperative Pain
(MIDL-SCS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a new type of spinal cord stimulation can reduce pain that persists after surgery and resists other treatments. It compares a new method (DL-SCS) to both a traditional method and no treatment. Participants will try different combinations of spinal cord stimulation and report changes in their pain. The trial seeks participants who have undergone surgery and continue to experience pain in one body part that does not improve with medication or therapy. As an unphased trial, it offers a unique opportunity to explore innovative pain management solutions that might not be available elsewhere.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this spinal cord stimulation is safe for treating postoperative pain?
Studies have shown that spinal cord stimulation (SCS) is generally safe and well-tolerated. Research indicates that after SCS, pain levels significantly improve, with some reports noting a 45% reduction in pain. However, rare cases of serious side effects, such as loss of movement in the legs, have occurred, though these are uncommon.
For DL-SCS (dorsolateral spinal cord stimulation) and M-SCS (another type of spinal cord stimulation) treatments, safety data is similar. Both methods have proven effective for managing chronic pain and have been used successfully. While long-term safety information is somewhat limited, available evidence suggests that both treatments are minimally invasive and generally safe for most patients.
Overall, despite some risks, SCS treatments are widely used and considered safe options for managing chronic pain.12345Why are researchers excited about this trial's treatments?
Researchers are excited about spinal cord stimulation (SCS) for postoperative pain because it works differently from standard pain medications, which often rely on opioids or NSAIDs. Unlike these traditional treatments, SCS uses electrical signals to interfere with the pain messages sent to the brain, potentially providing relief without the side effects associated with medications. This trial explores several SCS methods, including DL-SCS and M-SCS, which use high-frequency, paresthesia-free programs to avoid the tingling sensations common in older SCS technologies. By targeting the spinal cord directly, these approaches aim to offer a more effective and comfortable pain management solution post-surgery.
What evidence suggests that this trial's treatments could be effective for post-surgical neuropathic pain?
Studies have shown that spinal cord stimulation (SCS) can greatly reduce pain in people with long-term pain conditions. This trial may involve different types of SCS treatments for participants. Research indicates that 40% of patients experienced more than a 50% reduction in pain after DL-SCS treatment. M-SCS has also proven effective, with some studies showing a 45% improvement in pain levels. Using DL-SCS and M-SCS together may offer even better pain relief, as each method works differently. Overall, SCS treatments have shown promise in reducing pain and improving the quality of life for many patients.16789
Who Is on the Research Team?
Lutz Weise, MD, PhD
Principal Investigator
Nova Scotia Health Authority
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Stimulation On
Spinal cord stimulators are optimized and programmed to deliver high frequency stimulation below detectable threshold for 6 weeks
Treatment - Stimulation Off
Spinal cord stimulators are optimized and programmed to deliver no stimulation for 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Spinal Cord Stimulation
Spinal Cord Stimulation is already approved in United States, European Union, Canada for the following indications:
- Failed back surgery syndrome (FBSS)
- Adhesive arachnoiditis
- Peripheral causalgia/neuropathy
- Reflex sympathetic dystrophy (RSD)
- Phantom limb/stump pain
- Ischemic pain of vascular origin
- Complex regional pain syndrome
- Pain after an amputation
- Visceral abdominal pain and perineal pain
- Chronic pain
- Neuropathic pain
- Spinal cord injury pain
- Failed back surgery syndrome (FBSS)
- Adhesive arachnoiditis
- Peripheral causalgia/neuropathy
- Reflex sympathetic dystrophy (RSD)
- Chronic pain
- Neuropathic pain
- Spinal cord injury pain
- Failed back surgery syndrome (FBSS)
- Adhesive arachnoiditis
- Peripheral causalgia/neuropathy
- Reflex sympathetic dystrophy (RSD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nova Scotia Health Authority
Lead Sponsor